Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
NATICK, Mass., Feb. 28 -- Boston Scientific Corporation (NYSE:BSX) today announced the first European implants of its COGNIS(TM) cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM) implantable cardioverter defibrillator (ICD). Physicians began performing implants earlier this week. Forty implants have been performed in 14 hospitals in six countries.
When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features. The COGNIS CRT-D and the TELIGEN ICD are designed to eliminate those compromises. They are among the world's smallest and thinnest high-energy devices at 32.5 cc and 31.5 cc respectively, while less than 10 mm thick. They offer features based on significant engineering advances, including extended battery longevity, self- correcting software and improved programming technology. These devices are built on an entirely new technology platform and are the result of a multi- year research and development effort to provide physicians enhanced clinical options for their patients.
The COGNIS CRT-D and TELIGEN ICD received CE Mark last month. This week's implants represent the beginning of the market launch in Europe. The Company plans to build to a full launch in Europe and other international markets in the second quarter.
"The COGNIS CRT-D offers extended battery longevity and several new features that will help me better manage my heart failure patients," said Poul-Erik Bloch-Thomsen, M.D., Gentofte Hospital, Hellerup, Denmark. "For example, the SmartDelay(TM) feature recommends programmable device settings, which enable me to tailor individualized pacing therapies."
"The TELIGEN ICD has comprehensive programming options that address the requirements of both physicians and patients," said Lieselotte van Erven, M.D., Leiden University Medical Center, Leiden, The Netherlands. "The device offers me flexibility for delivering defibrillation to my patients and helps ensure that the right therapy is delivered at the appropriate time."
"These devices are further evidence of our commitment to research and development, and they are the latest indications of how we have refocused our cardiac rhythm management business on the needs of physicians and patients," said Jim Tobin, President and Chief Executive Officer of Boston Scientific.
The COGNIS CRT-D and the TELIGEN ICD are pending approval by the U.S. Food and Drug Administration and are not available for sale in the United States.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
CONTACT:
Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation
Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation
Source: Boston Scientific Corporation
Web site: www.bostonscientific.com/
